Jasper Therapeutics (JSPR) Return on Capital Employed (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Return on Capital Employed of 250.97% for Q4 2025, down 14852.0% year-over-year from N/an in Q4 2024, and up 16.84% quarter-over-quarter from 301.78% in Q3 2025.
Jasper Therapeutics (JSPR) Return on Capital Employed (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 250.97% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 14852.0% year-over-year to 250.97%; the TTM figure through Dec 2025 stood at 250.97% (down 14852.0% YoY), while the FY2025 annual figure was 187.91%, down 8226.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 250.97%, up from 301.78% in the prior quarter.
- The five-year high for Return on Capital Employed was 26.53% in Q2 2021, with the low at 301.78% in Q3 2025.
- The 5-year median for Return on Capital Employed is 68.54% (2022), against an average of 99.87%.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed jumped 3342 bps in 2023, then tumbled 23625 bps in 2025.
- Jasper Therapeutics' Return on Capital Employed stood at 39.86% in 2021, then plunged by 175 bps to 109.7% in 2022, then jumped by 30 bps to 76.28% in 2023, then tumbled by 34 bps to 102.45% in 2024, then slumped by 145 bps to 250.97% in 2025.
- Business Quant data shows JSPR's Return on Capital Employed at 250.97% in Q4 2025, 301.78% in Q3 2025, and 298.28% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -250.97% |
| Sep 30, 2025 | -301.78% |
| Jun 30, 2025 | -298.28% |
| Mar 31, 2025 | -147.07% |
| Dec 31, 2024 | -102.45% |
| Sep 30, 2024 | -72.90% |
| Jun 30, 2024 | -62.03% |
| Mar 31, 2024 | -68.94% |
| Dec 31, 2023 | -76.28% |
| Sep 30, 2023 | -61.57% |
| Jun 30, 2023 | -47.54% |
| Mar 31, 2023 | -61.13% |
| Dec 31, 2022 | -109.70% |
| Sep 30, 2022 | -86.42% |
| Jun 30, 2022 | -68.14% |
| Mar 31, 2022 | -53.44% |
| Dec 31, 2021 | -39.86% |
| Sep 30, 2021 | -32.42% |
| Jun 30, 2021 | -26.53% |
| Mar 31, 2021 | -29.93% |